GTHP Stock — Guided Therapeutics Inc

Guided Therapeutics Inc (GTHP)

Updated October 16, 2026.

GTHP is a Stock. Its deepest 1-year drawdown was 66.7%.

Guided Therapeutics is a medical technology company that develops and distributes medical devices, including LuViva, an advanced cervical scan system designed for non-invasive cervical cancer detection and screening. The company does not currently distribute dividends to shareholders. This security may appeal primarily to investors seeking exposure to healthcare innovation and medical device development rather than those focused on current income generation.

GTHP performance

Returns are updating. GTHP's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 66.7%.

GTHP key facts

Asset type

Stock

Asset class

Equity

Inception date

07/01/1997

Distribution frequency

None

Last close

$0.19 (as of 2026-10-16)

Market cap

$18,342,096

Average volume

110.0

Payment date

03/29/2019

Beta

0.699

Payout ratio

0.0%

EPS

$-0.04

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GTHP risks and drawbacks

The deepest 1-year drawdown on record here is 66.7%.

Who may consider GTHP — and who may not

It is a weaker fit for investors who need monthly cash flow (GTHP does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on GTHP

• All tickers starting with G

Tagged: Healthcare.

Frequently asked questions